Fidasimtamab, designated DLTV – 1504, represents a novel avenue in the treatment against multiple myeloma. The drug is a targeted agent designed to together engage CD3-positive lymphocytes and multiple https://www.targetmol.com/compound/fidasimtamab
{Fidasimtamab: This New Treatment in Relapsed/Refractory Plasma Cell Therapy ?
Internet - 3 hours ago fidasimtamab-research-gr786282
Web Directory Categories
Web Directory Search
New Site Listings